Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Wegener Polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores, and fever. Predisposing factor includes age. Treatment includes immunosuppressive and corticosteroids.
The Granulomatosis with Polyangiitis drugs in development market research report provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Granulomatosis with Polyangiitis and features dormant and discontinued projects.
Key Targets in the Granulomatosis with Polyangiitis Pipeline Products Market
The key targets in the Granulomatosis with Polyangiitis pipeline products market are Cells Expressing B Lymphocyte Antigen CD20, Interleukin 5, Complement C5, Interleukin 2 Receptor, Interleukin 5 Receptor Subunit Alpha, Interleukin 6 Receptor, T Lymphocyte Activation Antigen CD80, T Lymphocyte Activation Antigen CD86, and Tyrosine Protein Kinase JAK1.
Granulomatosis with Polyangiitis Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Granulomatosis with Polyangiitis Pipeline Products Market
The key mechanisms of action in the Granulomatosis with Polyangiitis pipeline products market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Interleukin 5 Inhibitor, Complement C5 Inhibitor, Interleukin 2 Receptor Agonist, Interleukin 5 Receptor Subunit Alpha Antagonist, Interleukin 6 Receptor Antagonist, T Lymphocyte Activation Antigen CD80 Inhibitor, T Lymphocyte Activation Antigen CD86 Inhibitor, and Tyrosine Protein Kinase JAK1 Inhibitor.
Granulomatosis with Polyangiitis Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
Key Routes of Administration in the Granulomatosis with Polyangiitis Pipeline Products Market
The key routes of administration in the Granulomatosis with Polyangiitis pipeline products market are intravenous, subcutaneous, oral, and parenteral.
Granulomatosis with Polyangiitis Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Granulomatosis with Polyangiitis Pipeline Products Market
The key molecule types in the Granulomatosis with Polyangiitis pipeline products market are monoclonal antibody, fusion protein, and recombinant protein.
Granulomatosis with Polyangiitis Pipeline Products Market Analysis by Molecule Type
For more molecule type insights, download a free report sample
Major Companies in the Granulomatosis with Polyangiitis Pipeline Products Market
Some of the major companies in the Granulomatosis with Polyangiitis pipeline products market are GlaxoSmithKline Plc, Biogen Inc, Bristol-Myers Squibb Co, Chugai Pharmaceutical Co Ltd, iBio Inc, Iltoo Pharma, InflaRx NV, Kyowa Kirin Co Ltd, Mabion SA, and Nanolek.
Granulomatosis with Polyangiitis Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Overview
Key targets | Cells Expressing B Lymphocyte Antigen CD20, Interleukin 5, Complement C5, Interleukin 2 Receptor, Interleukin 5 Receptor Subunit Alpha, Interleukin 6 Receptor, T Lymphocyte Activation Antigen CD80, T Lymphocyte Activation Antigen CD86, and Tyrosine Protein Kinase JAK1 |
Key mechanism of action | Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Interleukin 5 Inhibitor, Complement C5 Inhibitor, Interleukin 2 Receptor Agonist, Interleukin 5 Receptor Subunit Alpha Antagonist, Interleukin 6 Receptor Antagonist, T Lymphocyte Activation Antigen CD80 Inhibitor, T Lymphocyte Activation Antigen CD86 Inhibitor, and Tyrosine Protein Kinase JAK1 Inhibitor |
Key routes of administration | Intravenous, Subcutaneous, Oral, and Parenteral |
Key molecule type | Monoclonal Antibody, Fusion Protein, and Recombinant Protein |
Major companies | GlaxoSmithKline Plc, Biogen Inc, Bristol-Myers Squibb Co, Chugai Pharmaceutical Co Ltd, iBio Inc, Iltoo Pharma, InflaRx NV, Kyowa Kirin Co Ltd, Mabion SA, and Nanolek |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Granulomatosis with Polyangiitis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Granulomatosis with Polyangiitis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Granulomatosis with Polyangiitis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Granulomatosis with Polyangiitis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Granulomatosis with Polyangiitis (Immunology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Granulomatosis with Polyangiitis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Granulomatosis with Polyangiitis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Bristol-Myers Squibb Co
Chugai Pharmaceutical Co Ltd
GlaxoSmithKline Plc
iBio Inc
Iltoo Pharma
InflaRx NV
Kyowa Kirin Co Ltd
Mabion SA
Nanolek
Nichi-Iko Pharmaceutical Co Ltd
Nippon Shinyaku Co Ltd
Pharmapraxis
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Granulomatosis with Polyangiitis pipeline products market?
The key targets in the Granulomatosis with Polyangiitis pipeline products market are Cells Expressing B Lymphocyte Antigen CD20, Interleukin 5, Complement C5, Interleukin 2 Receptor, Interleukin 5 Receptor Subunit Alpha, Interleukin 6 Receptor, T Lymphocyte Activation Antigen CD80, T Lymphocyte Activation Antigen CD86, and Tyrosine Protein Kinase JAK1.
-
What are the key mechanisms of action in the Granulomatosis with Polyangiitis pipeline products market?
The key mechanisms of action in the Granulomatosis with Polyangiitis pipeline products market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Interleukin 5 Inhibitor, Complement C5 Inhibitor, Interleukin 2 Receptor Agonist, Interleukin 5 Receptor Subunit Alpha Antagonist, Interleukin 6 Receptor Antagonist, T Lymphocyte Activation Antigen CD80 Inhibitor, T Lymphocyte Activation Antigen CD86 Inhibitor, and Tyrosine Protein Kinase JAK1 Inhibitor.
-
What are the key routes of administration in the Granulomatosis with Polyangiitis pipeline products market?
The key routes of administration in the Granulomatosis with Polyangiitis pipeline products market are intravenous, subcutaneous, oral, and parenteral.
-
What are the key molecule types in the Granulomatosis with Polyangiitis pipeline products market?
The key molecule types in the Granulomatosis with Polyangiitis pipeline products market are monoclonal antibody, fusion protein, and recombinant protein.
-
Which are the major companies in the Granulomatosis with Polyangiitis pipeline products market?
Some of the major companies in the Granulomatosis with Polyangiitis pipeline products market are GlaxoSmithKline Plc, Biogen Inc, Bristol-Myers Squibb Co, Chugai Pharmaceutical Co Ltd, iBio Inc, Iltoo Pharma, InflaRx NV, Kyowa Kirin Co Ltd, Mabion SA, and Nanolek.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.